Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Up 25.7% in December

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Currently, 7.4% of the company’s shares are short sold. Based on an average trading volume of 286,800 shares, the short-interest ratio is presently 11.8 days.

Analysts Set New Price Targets

Several equities analysts have recently commented on ATXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Monday. Oppenheimer increased their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.60.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently modified their holdings of the stock. Quest Partners LLC raised its position in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. PDT Partners LLC purchased a new position in Astria Therapeutics in the third quarter worth approximately $140,000. SG Americas Securities LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth approximately $155,000. Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the 2nd quarter worth approximately $171,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Astria Therapeutics in the 3rd quarter valued at approximately $228,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of ATXS stock traded down $0.25 during trading on Friday, reaching $7.50. The company’s stock had a trading volume of 237,439 shares, compared to its average volume of 327,213. The company has a market capitalization of $423.23 million, a price-to-earnings ratio of -3.59 and a beta of 0.70. Astria Therapeutics has a 1-year low of $6.95 and a 1-year high of $16.90. The stock’s 50-day moving average price is $9.52 and its 200 day moving average price is $10.63.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.